LRIG1 levels in chronic rhinosinusitis with nasal polyps

MakaleAçık Erişim
  • SDG 3 · Sağlık ve Kaliteli Yaşam

Özet

Purpose: Nasal polyps (NPs), usually occurring together with chronic rhinosinusitis (CRS), are benign masses of mucosal origin arising from inflammation. The transmembrane protein known as leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) is a member of the Lrig family. Lrig1 is frequently expressed in the respiratory tract and epithelial tissues and can inhibit several signaling pathways involved in cell proliferation. The aim of this study was to determine Lrig1 levels in NP tissues of patients with CRS. Material and Methods: This study included 36 patients with CRS and NPs and 15 patients who underwent rhinoplasty as the control group. The Lrig1 levels of all participants were measured by the ELISA method.Results: This study revealed that Lrig1 levels were significantly lower in NP tissues than in tissues of the control group. The mean level of Lrig1 of the NP tissues was 22.2 ng/ml, while the mean level of the control group was 28.5 ng/ml. According to the results of ROC analysis, Lrig1 levels have the power to distinguish polyp tissues from control tissues (AUC=0.794). Lrig1 levels were higher in tissues with scores of 4-8 than in tissues with scores of 16-20 based on the results of computed tomography scoring. According to endoscopic evaluations, Lrig1 levels of tissues with scores of 5-8 or 9-11 were relatively lower than those of tissues with scores of 2-4.Conclusion: Lrig1 levels were found to be decreased in NP tissues. Thus, Lrig1 may be used to confirm the presence of NPs. Lrig1 may also be helpful in NP grading. Increasing the Lrig1 levels in cases of NPs has the potential to become a targetable treatment modality.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/bayburt/14329Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.17826/cumj.1230714Yayıncı resmi DOI adresi
İndeks kayıtları
Kaydın indeks veri tabanlarındaki sayfası (aktarımda alınan kayıt numarasıyla). Erişim, indeksin kendi koşullarına bağlıdır.
Atıflar
WoS
1
OpenAlex
1
TR Dizin
1
Her kaynağın kendi saydığı toplam atıf; aktarım ve zenginleştirme sırasında alındı.
Tam Kayıt
AlanDeğerDil
dc.contributor.authorUzunçakmak, Sevgi Karabulut
dc.contributor.authorSahin, Abdulkadir
dc.contributor.authorÖzçelik, Aysegul Tavaci
dc.contributor.authorHalici, Zekai
dc.date.accessioned2026-10-29T19:15:44.093406077Z
dc.date.available2026-10-29T19:15:44.093406077Z
dc.date.issued2023
dc.description.abstractPurpose: Nasal polyps (NPs), usually occurring together with chronic rhinosinusitis (CRS), are benign masses of mucosal origin arising from inflammation. The transmembrane protein known as leucine-rich repeats and immunoglobulin-like domains 1 (Lrig1) is a member of the Lrig family. Lrig1 is frequently expressed in the respiratory tract and epithelial tissues and can inhibit several signaling pathways involved in cell proliferation. The aim of this study was to determine Lrig1 levels in NP tissues of patients with CRS. Material and Methods: This study included 36 patients with CRS and NPs and 15 patients who underwent rhinoplasty as the control group. The Lrig1 levels of all participants were measured by the ELISA method.Results: This study revealed that Lrig1 levels were significantly lower in NP tissues than in tissues of the control group. The mean level of Lrig1 of the NP tissues was 22.2 ng/ml, while the mean level of the control group was 28.5 ng/ml. According to the results of ROC analysis, Lrig1 levels have the power to distinguish polyp tissues from control tissues (AUC=0.794). Lrig1 levels were higher in tissues with scores of 4-8 than in tissues with scores of 16-20 based on the results of computed tomography scoring. According to endoscopic evaluations, Lrig1 levels of tissues with scores of 5-8 or 9-11 were relatively lower than those of tissues with scores of 2-4.Conclusion: Lrig1 levels were found to be decreased in NP tissues. Thus, Lrig1 may be used to confirm the presence of NPs. Lrig1 may also be helpful in NP grading. Increasing the Lrig1 levels in cases of NPs has the potential to become a targetable treatment modality.
dc.identifier.doi10.17826/cumj.1230714
dc.identifier.eissn2602-3040
dc.identifier.endpage329
dc.identifier.issn2602-3032
dc.identifier.issue2
dc.identifier.startpage323
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/bayburt/14329
dc.identifier.volume48
dc.identifier.wosWOS:001008335200001
dc.language.isoen
dc.publisherCUKUROVA UNIV, FAC MEDICINE
dc.relation.ispartofCUKUROVA MEDICAL JOURNAL
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectNasal polyps
dc.subjectLrig1
dc.subjectELISA
dc.subjectrhinosinusitis
dc.subject.classificationMedicine, General & Internal
dc.subject.classificationGeneral & Internal Medicine
dc.subject.otherNEGATIVE REGULATOR LRIG1
dc.subject.otherEPIDERMAL-GROWTH-FACTOR
dc.subject.otherFACTOR RECEPTOR
dc.subject.otherSTEM
dc.subject.otherEXPRESSION
dc.subject.otherCELLS
dc.subject.otherSUPPRESSION
dc.subject.otherHOMEOSTASIS
dc.subject.otherPATHWAY
dc.titleLRIG1 levels in chronic rhinosinusitis with nasal polyps
dc.typeArticle
rdl.citation.openalex1
rdl.citation.trdizin1
rdl.citation.wos1
rdl.oa.statusgold
rdl.oa.urlhttps://dergipark.org.tr/en/download/article-file/2877403
rdl.sdgSDG03
rdl.source.indexWOS
rdl.source.indexTRDIZIN
rdl.wos.indexEmerging Sources Citation Index (ESCI)